References
- Cancer incidence of Sweden, Centre for Epidemiology. National Board of Health and Welfare: Stockholm; 2009.
- Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer Results Study Group. Br J Urol Int 2012:109;s1.
- Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localised prostate cancer. JAMA 2005;293:2095–101.
- Jane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: CAP and Protec T studies. Eur J Cancer 2010;46:3095–10.
- Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Cancer 2009;115:3446–56.
- Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomized trials of neo-adjuvant hormone therapy for localized and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.
- Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment with or without radiotherapy in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial. Lancet 2009;373:301–8.
- Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: Effects on health-related quality of life. Br J Urol Int 2005;96:43–7.
- Grenabo L, Grundtman S, Hedelin H. Laparoscopic obturator lymph node dissection in patients with prostate cancer. Scand J Urol Nephrol 1995;29:51–5.
- Walsh PC, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 1984; 56;694–7.
- Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of cancer QLQ C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
- Fayers P. EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: EORTC; 2001.
- Paulson DF. Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. NCI Mono 1988;(7):127–31.
- Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502–4.
- Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Hormonal treatment before radical prostatectomy: A 3-year follow-up. J Urol 1998;159: 2013–6; Discussion 2016–7.
- Wahlgren T, Nilsson S, Ryberg M, Lennernäs B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005;44:633–43.
- Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192) ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys 2004;60:51–9.